Our customers are breaking new ground with their research

"We gain new insight when measuring the interaction of genetics and epigenetics on the same read… We look forward to progressing our research with technology and affecting a paradigm shift in the way cancer can be treated and monitored in the clinic."

"Circulating tumor DNA (ctDNA) analysis has become a promising and minimally invasive strategy for cancer detection and disease monitoring. Yet, in localized prostate cancer, detection of ctDNA remains highly challenging due to the low fraction of tumor-derived DNA in circulation. To address this limitation, we aim to develop a multimodal approach that combines epigenetic modifications with fragmentomic features. This integrative strategy is designed to improve both the sensitivity and specificity of ctDNA detection in early-stage prostate cancer. Multimodal approaches such as this hold the greatest promise for overcoming current technical barriers and enabling more reliable detection in the low-shedding context of localized disease."

“Unlocking new capabilities is crucial to better understanding the genome because the pre-cancerous mutations that we study are in genes that affect methylation and hydroxymethylation. Being able to simultaneously read both the germline genetic variance and methylation helps us understand where the methylation is happening, which provides us with a better idea of how these inherited genetic variants may shape the pre-cancer. The information you get is not possible to recapitulate with multiple assays, which makes this technology incredibly valuable to our research.”

"Accessing the 6-base genome and relating methylation and hydroxymethylation to specific variants in our breast cancer work could increase the sensitivity for ctDNA detection in liquid biopsy, enabling earlier detection. We also see promise in the ability of these methylation marks to determine gene expression, chromatin accessibility and gene regulation, and look forward to exploring this potential with the biomodal team."

"It's becoming more evident that distinguishing between 5mC and 5hmC modifications is crucial in order to understand the epigenetic landscape in detail. Current methods that are able to do this, are only able to do this separately, this leads to the need for multiple workflows and this increases the cost, time and sample requirements. In addition, methods such as bisulphite sequencing are very harsh on the DNA and this can lead to loss of samples throughout the analysis. duet evoC is able to overcome these issues and is able to identify 5mC and 5hmC modifications in a single workflow with a very low sample input of 5ng of DNA"